Thanks to DATIA for this UPDATE:<\/p>\r\n\r\n\r\n\r\n
On August 8, 2017, a newly revised\u00a0Federal Custody & Control Form (CCF)<\/strong><\/a>\u00a0was approved for use by HHS-regulated employers and service agents. However,\u00a0DOT-regulated employers and their service agents are not permitted to use the revised CCF for testing under 49 CFR Part 40 because DOT has not yet issued a final rule authorizing testing for synthetic opioids. So, what does this mean for DOT employers and service agents? While OMB was approving the revised CCF, they also approved the extended use of the\u00a0\u2018old\u2019\u00a0CCF until June 30, 2018. As a result,\u00a0DOT-regulated employers and their service agents (collectors, laboratories, Medical Review Officers) are to continue using the \u2018old\u2019 CCF until further notice from DOT\u2019s Office of Drug and Alcohol Policy and Compliance.\u00a0 When using the ‘old’ CCF \u2013 the one that has been used under the DOT-regulated program since 2010 \u2013 a “memorandum for the record” is not required.\u00a0If the revised (2017 version) CCF is used inadvertently for a DOT test and the testing was consistent with Part 40, MROs are to verify and report the result according to Part 40.\u00a0For more information, visit the\u00a0DOT’s website<\/a>.(DATIA merged with\u00a0NDASA<\/a>\u00a0in 2023)<\/p>\r\n","protected":false},"excerpt":{"rendered":" Thanks to DATIA for this UPDATE: On August 8, 2017, a newly revised\u00a0Federal Custody & Control Form (CCF)\u00a0was approved for use by HHS-regulated employers and service agents. However,\u00a0DOT-regulated employers and their service agents are not permitted to use the revised CCF for testing under 49 CFR Part 40 because DOT has not yet issued a […]<\/p>\n","protected":false},"author":12,"featured_media":51694,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[45],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55038"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=55038"}],"version-history":[{"count":1,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55038\/revisions"}],"predecessor-version":[{"id":118388,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55038\/revisions\/118388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/51694"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=55038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=55038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=55038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}